A Phase 2 interventional study of Lapatinib and Capecitabine in Cancer, sponsored by Novartis Pharmaceuticals. Terminated at 17 sites in 5 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-07-15.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 114 studies testing lapatinib in Breast Neoplasms — none open to participants now, 3 under way, 1 of them phase 3. Lapatinib · Breast Neoplasms.
Among the 114 studies testing lapatinib in Breast Neoplasms, this one is the 38th largest by enrollment, is one of 4 that started in 2014, is one of 60 in phase 2, and was the 112th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →None of the 114 studies testing lapatinib in Breast Neoplasms is open now. The open studies under Breast Neoplasms, anywhere →
Lapatinib: first FDA approval 2007 (TYKERB), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
114 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 36 · Phase 2 70 · Phase 3 18
First in 2003; this study’s year is marked. 4 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 62 is below the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 35 across the 114 interventional studies. Of the 99 that completed or were terminated, 50 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
48 of 114 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
199 studies in Breast Neoplasms by Novartis: 16 open now, 30 under way, 4 of them phase 3. Of 160 finished, 74 (46%) have results posted.
Among the 199 studies in Breast Neoplasms by Novartis, this one is the 97th largest by enrollment of the 155 interventional ones that give a count, is one of 13 that started in 2014, is one of 39 in phase 2, and was the 117th registered.
Novartis’s Breast Neoplasms studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 114 studies testing lapatinib in Breast Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 199 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
Diarrhoea is the most commonly reported adverse event (AE) associated with Lapatinib treatment, and is also commonly associated with Capecitabine treatment. Although these events are generally mild to moderate in severity, diarrhoea adversely affects the tolerability of cancer treatment, and in severe cases diarrhoea has the potential to affect the efficacy of treatment due to poor compliance, or treatment interruption or withdrawal. The efficacy of Octreotide in the management of cancer treatment-associated diarrhoea has not been extensively evaluated in large, well-controlled studies. This is a randomised, multi-centre, open-label Phase II study in subjects with Human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer which has progressed following prior therapy, which must have included anthracyclines and taxanes and therapy with Trastuzumab in the metastatic setting. This study is not placebo controlled, and there is no active comparator. The study evaluates whether the prophylactic use of Octreotide Long Acting Release (LAR) offers a clinically meaningful benefit by reducing the frequency and severity of diarrhoea associated with treatment with Lapatinib and Capecitabine. Study completion for a subject is defined as the completion of 24 weeks of treatment with Lapatinib and Capecitabine, or progression of cancer or the death of the subject during treatment, whichever occurs first. Approximately 140 subjects were planned to be randomized out of which 70 were planned to receive octreotide and 70 were planned to receive no Octreotide.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
This study's enrollment of 62 is below the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Browse Breast Neoplasms studies →Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Compared within Breast Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Incapable of becoming pregnant, or not pregnant and using an adequate form of , i.e. a female who is of:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects randomised to receive Octreotide were administered with Octreotide (Sandostatin LAR™) 40mg 7 days before the start of treatment with Lapatinib and Capecitabine and again 28 days later. All subjects received treatment with Lapatinib 1250milligram (mg) once daily and Capecitabine 1000 milligram/square meter (mg/m\^2) twice daily until disease progression. Lapatinib was given every day; Capecitabine was given in 3 week cycles of two weeks treatment followed by one week off treatment. SANDOSTATIN™ is a trademark of Novartis.
Drug: Lapatinib · Drug: Capecitabine · Drug: Octreotide
Subjects randomised to receive no octreotide, treatment with Lapatinib and Capecitabine was initiated immediately following enrolment. All subjects received treatment with Lapatinib 1250mg once daily and Capecitabine 1000mg/m\^2 twice daily until disease progression. Lapatinib was given every day; Capecitabine was given in 3 week cycles of two weeks treatment followed by one week off treatment
Drug: Lapatinib · Drug: Capecitabine
Lapatinib was supplied as 250mg tablets that are oval, biconvex, and orange film-coated with one side plain and the opposite side debossed, or as 250mg tablets that are oval, biconvex, and yellow film-coated with one side plain and the opposite side debossed. Each tablet contained 405mg of Lapatinib ditosylate monohydrate, equivalent to 250mg Lapatinib free base
Capecitabine (Xeloda™) was supplied as a biconvex, oblong, light peach or peach colored film-coated tablet for oral administration. Each light peach colored tablet contained 150mg Capecitabine and each peach colored tablet contained 500mg Capecitabine. Generic versions of capecitabine may have been used within the study if Xeloda cannot be provided. XELODA™ is a trademark of Hoffmann-La Roche AG.
Octreotide (Sandostatin LAR™) was supplied as sterile 5milliliter (mL) vials delivering 20mg Octreotide as the free peptide. When mixed with diluent (approximately 2mL or 2.5 mL) it becomes a suspension that is given as an intramuscular injection. Two 20mg intramuscular injections were given to deliver a total dose of 40mg. The Octreotide is uniformly distributed within the microspheres which are made of a biodegradable glucose star polymer, D,L-lactic and glycolic acids copolymer. Sterile mannitol was added to the microspheres to improve suspendability
Proportion of Subjects Experiencing Diarrhoea of Grade 2 and Above (up to 24 Weeks)
Proportion of subjects experiencing at least one episode of diarrhoea with a severity of Grade 2 and above, as defined by the National Cancer Institute common terminology criteria for adverse events (NCI CTCAE) version 4.03, recorded as AEs in the Electronic case report form (eCRF)
Time frame: Up to 24 weeks
Proportion of Subjects Experiencing Diarrhoea of Grade 3 and Above (up to 24 Weeks)
Proportion of subjects experiencing diarrhoea with a severity of Grade 3 and above, as defined by the NCI CTCAE, version 4.03 and recorded as AEs in the eCRF
Time frame: Up to 24 weeks
Proportion of Subjects Experiencing Diarrhoea of Any Grade of Severity (up to 24 Weeks)
Proportion of subjects experiencing diarrhoea of any grade of severity as defined by the NCI CTCAE, version 4.03 and recorded as AEs in the eCRF
Time frame: Up to 24 weeks
Duration of Diarrhoea of Any Grade of Severity
Duration of diarrhoea of any grade of severity, recorded as AEs in the eCRF
Time frame: Up to 24 weeks
Time to Onset of the First Episode of Diarrhoea of Any Grade of Severity
Time to onset of the first episode of diarrhoea of any grade of severity, recorded as an AE in the eCRF. Subject are censored if there was no event. Median time and 95% confidence intervals were calculated using Kaplan-Meier estimates.
Time frame: Up to 24 weeks
Proportion of Subjects Taking Anti-diarrhoeal Medication
Proportion of subjects taking anti-diarrhoeal medication as recorded in the eCRF
Time frame: Up to 24 weeks
Proportion of Subjects Who Had Unscheduled Visits to Healthcare Professionals Due to Diarrhoea
Proportion of subjects making diarrhoea related unscheduled visits to healthcare professionals as recorded in the eCRF
Time frame: Up to 24 weeks
Proportion of Subjects Requiring Dose Reduction in Lapatinib and Capecitabine
Proportion of subjects requiring diarrhoea related Lapatinib and Capecitabine dose reduction as recorded in the eCRF
Time frame: Up to 24 weeks
Proportion of Subjects Requiring Dose Delay in Lapatinib and Capecitabine
Proportion of subjects requiring diarrhoea related Lapatinib and Capecitabine dose delay as recorded in the eCRF
Time frame: Up to 24 weeks
Proportion of Subjects Requiring Treatment Withdrawal in Lapatinib and Capecitabine
Proportion of subjects requiring diarrhoea related Lapatinib and Capecitabine treatment withdrawal as recorded in the eCRF
Time frame: Up to 24 weeks
Proportion of Subjects Requiring Use of Diarrhoea-related Intravenous Fluids
Proportion of subjects requiring use of diarrhoea-related intravenous fluids for rehydration as recorded in the eCRF
Time frame: Up to 24 weeks
Number of Lapatinib and Capecitabine Tablets Dispensed and Returned
Number of Lapatinib and Capecitabine tablets dispensed and returned as recorded in the eCRF
Time frame: Up to 24 weeks
Overall Response Rate (up to 24 Weeks)
Overall response rate as measured in accordance with the Response Evaluation Criteria In Solid Tumours (RECIST) version 1.1. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Progressive Disease (PD) \>=20% and \>= 5mm increase in the sum of diameters of target lesions; Stable Disease (SD), Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.
Time frame: Up to 24 weeks
Clinical Benefit Response (up to 24 Weeks)
Clinical benefit response as measured in accordance with the Response Evaluation Criteria In Solid Tumours (RECIST) version 1.1. Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. Clinical Benefit Response rate (CBR) is defined as the percentage of subjects with a CR, PR or SD at week 24.
Time frame: Up to 24 weeks
Proportion of Subjects Reporting Changes in Bowel Movements From Baseline (Frequency and/or Consistency) as Recorded in the Diarrhoea Management Diary (DMD)
All subjects completed the baseline DMD during the 3 days prior to randomisation, before any study-related treatment is administered. Subjects randomised to receive Octreotide completed a second baseline DMD before starting the first cycle of treatment with Lapatinib and Capecitabine. The baseline DMD comprised of 3 questions to record stool form and consistency. The DMD to be completed throughout the rest of the study comprised of 3 questions in the baseline DMD and a further 5 questions and 6 sub-questions to evaluate the consequences and management of diarrhoea.
Time frame: Up to 24 weeks
Time to the First Subject Reported Change in Frequency and/or Consistency of Bowel Movements From Baseline as Recorded in the DMD
Event is defined as Subjects reporting change in frequency and/or consistency of bowel movements from baseline at least once in DMD. Subject are censored if there is no change in bowel movement frequency/consistency as compared to baseline. Median time and 95% confidence intervals were calculated using Kaplan-Meier estimates.
Time frame: Up to 24 weeks
Proportion of Subjects Taking Anti-diarrhoeal Medication as Recorded in the DMD
The proportion of subjects taking medication at least once as a result of diarrhoea are summarised
Time frame: Up to 24 weeks
Proportion of Subjects Making Dietary Changes Due to Diarrhoea as Recorded in the DMD
The proportion of subjects making dietary changes to help with the diarrhoea are summarised
Time frame: Up to 24 weeks
Proportion of Subjects Contacting Other Non-hospital Healthcare Professionals to Discuss Diarrhoea as Recorded in the DMD
The proportion of subjects contacting a health care professional other than the hospital doctors/nurses to discuss diarrhoea are summarised
Time frame: Up to 24 weeks
Proportion of Subjects Reporting Stopping Completely or Missing Doses of Anti-cancer Tablets Due to Diarrhoea as Recorded in the DMD
The proportion of subjects reducing or completely stopping the number of anti-cancer tablets to help with diarrhoea are summarised
Time frame: Up to 24 weeks
The study enrolled 62 women in 17 centers; Czech Republic (1), Israel (1), Poland (3), the United Kingdom (4) Russian Federation (8)
| Milestone | Octreotide Treatment | No Octreotide Treatment |
|---|---|---|
| Started | 30 | 32 |
| Safety population | 29 | 33 |
| Itt population | 30 | 32 |
| Completed | 19 | 18 |
| Not completed | 11 | 14 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Withdrew: Physician decision | 6 | 7 |
| Withdrew: Lost to follow-up | 1 | 2 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Death | 2 | 3 |
Proportion of subjects experiencing at least one episode of diarrhoea with a severity of Grade 2 and above, as defined by the National Cancer Institute common terminology criteria for adverse events (NCI CTCAE) version 4.03, recorded as AEs in the Electronic case report form (eCRF)
| Participants | Octreotide Treatment | No Octreotide Treatment |
|---|---|---|
| Cyclce 1-3 (up to 9 weeks)with impuation | 7 | 9 |
| Cyclce 1-8 (up to 24 weeks)without imputation | 6 | 5 |
Proportion of subjects experiencing diarrhoea with a severity of Grade 3 and above, as defined by the NCI CTCAE, version 4.03 and recorded as AEs in the eCRF
| Participants | Octreotide Treatment | No Octreotide Treatment |
|---|---|---|
| Proportion of Subjects Experiencing Diarrhoea of Grade 3 and Above (up to 24 Weeks) | 2 | 0 |
Proportion of subjects experiencing diarrhoea of any grade of severity as defined by the NCI CTCAE, version 4.03 and recorded as AEs in the eCRF
| Participants | Octreotide Treatment | No Octreotide Treatment |
|---|---|---|
| Proportion of Subjects Experiencing Diarrhoea of Any Grade of Severity (up to 24 Weeks) | 18 | 14 |
Duration of diarrhoea of any grade of severity, recorded as AEs in the eCRF
| days | Octreotide Treatment | No Octreotide Treatment |
|---|---|---|
| Duration of Diarrhoea of Any Grade of Severity | 8.7 ± 11.15 | 36.8 ± 48.59 |
Time to onset of the first episode of diarrhoea of any grade of severity, recorded as an AE in the eCRF. Subject are censored if there was no event. Median time and 95% confidence intervals were calculated using Kaplan-Meier estimates.
| Days | Octreotide Treatment | No Octreotide Treatment |
|---|---|---|
| Time to Onset of the First Episode of Diarrhoea of Any Grade of Severity | NA (54.0 to NA) | 170 (104 to NA) |
Proportion of subjects taking anti-diarrhoeal medication as recorded in the eCRF
| Participants | Octreotide Treatment | No Octreotide Treatment |
|---|---|---|
| Proportion of Subjects Taking Anti-diarrhoeal Medication | 7 | 11 |
Proportion of subjects making diarrhoea related unscheduled visits to healthcare professionals as recorded in the eCRF
No measurements were reported for this outcome.
Proportion of subjects requiring diarrhoea related Lapatinib and Capecitabine dose reduction as recorded in the eCRF
| Participants | Octreotide Treatment | No Octreotide Treatment |
|---|---|---|
| Subjects requiring dose reduction in Lapatinib | 1 | 0 |
| Subjects requiring dose reduction in Capecitabine | 1 | 2 |
Proportion of subjects requiring diarrhoea related Lapatinib and Capecitabine dose delay as recorded in the eCRF
| Participants | Octreotide Treatment | No Octreotide Treatment |
|---|---|---|
| Subjects requiring dose delay in Lapatinib | 2 | 2 |
| Subjects requiring dose delay in Capecitabine | 2 | 2 |
Proportion of subjects requiring diarrhoea related Lapatinib and Capecitabine treatment withdrawal as recorded in the eCRF
| Participants | Octreotide Treatment | No Octreotide Treatment |
|---|---|---|
| Requiring treatment withdrawal in Lapatinib | 0 | 0 |
| Requiring treatment withdrawal in Capecitabine | 0 | 0 |
Proportion of subjects requiring use of diarrhoea-related intravenous fluids for rehydration as recorded in the eCRF
No measurements were reported for this outcome.
Number of Lapatinib and Capecitabine tablets dispensed and returned as recorded in the eCRF
| tablets | Octreotide Treatment | No Octreotide Treatment |
|---|---|---|
| Number of Lapatinib tablets dispensed | 1197.5 ± 403.12 | 1115.6 ± 495.9 |
| Number of Lapatinib tablets returned | 477.1 ± 173.94 | 403.3 ± 238.47 |
| Number of Capecitabine tablets dispensed | 1022.6 ± 473.44 | 1011.2 ± 532.06 |
| Number of Capecitabine tablets returned | 186.1 ± 157.19 | 210 ± 196.64 |
Overall response rate as measured in accordance with the Response Evaluation Criteria In Solid Tumours (RECIST) version 1.1. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Progressive Disease (PD) \>=20% and \>= 5mm increase in the sum of diameters of target lesions; Stable Disease (SD), Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.
| Participants | Octreotide Treatment | No Octreotide Treatment |
|---|---|---|
| complete response (CR) | 0 | 2 |
| partial response (PR) | 6 | 4 |
| stable disease (SD) | 4 | 5 |
| Progressive Disease | 14 | 17 |
| Not Evaluable | 6 | 4 |
Clinical benefit response as measured in accordance with the Response Evaluation Criteria In Solid Tumours (RECIST) version 1.1. Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. Clinical Benefit Response rate (CBR) is defined as the percentage of subjects with a CR, PR or SD at week 24.
| Participants | Octreotide Treatment | No Octreotide Treatment |
|---|---|---|
| Clinical Benefit Response (up to 24 Weeks) | 7 | 9 |
All subjects completed the baseline DMD during the 3 days prior to randomisation, before any study-related treatment is administered. Subjects randomised to receive Octreotide completed a second baseline DMD before starting the first cycle of treatment with Lapatinib and Capecitabine. The baseline DMD comprised of 3 questions to record stool form and consistency. The DMD to be completed throughout the rest of the study comprised of 3 questions in the baseline DMD and a further 5 questions and 6 sub-questions to evaluate the consequences and management of diarrhoea.
| Participants | Octreotide Treatment | No Octreotide Treatment |
|---|---|---|
| Proportion of Subjects Reporting Changes in Bowel Movements From Baseline (Frequency and/or Consistency) as Recorded in the Diarrhoea Management Diary (DMD) | 23 | 29 |
Event is defined as Subjects reporting change in frequency and/or consistency of bowel movements from baseline at least once in DMD. Subject are censored if there is no change in bowel movement frequency/consistency as compared to baseline. Median time and 95% confidence intervals were calculated using Kaplan-Meier estimates.
| Days | Octreotide Treatment | No Octreotide Treatment |
|---|---|---|
| Time to the First Subject Reported Change in Frequency and/or Consistency of Bowel Movements From Baseline as Recorded in the DMD | 22.0 (16.0 to 57.0) | 8.0 (8.0 to 15.0) |
The proportion of subjects taking medication at least once as a result of diarrhoea are summarised
| Participants | Octreotide Treatment | No Octreotide Treatment |
|---|---|---|
| Proportion of Subjects Taking Anti-diarrhoeal Medication as Recorded in the DMD | 2 | 2 |
The proportion of subjects making dietary changes to help with the diarrhoea are summarised
| Participants | Octreotide Treatment | No Octreotide Treatment |
|---|---|---|
| Proportion of Subjects Making Dietary Changes Due to Diarrhoea as Recorded in the DMD | 9 | 11 |
The proportion of subjects contacting a health care professional other than the hospital doctors/nurses to discuss diarrhoea are summarised
| Participants | Octreotide Treatment | No Octreotide Treatment |
|---|---|---|
| Proportion of Subjects Contacting Other Non-hospital Healthcare Professionals to Discuss Diarrhoea as Recorded in the DMD | 4 | 3 |
The proportion of subjects reducing or completely stopping the number of anti-cancer tablets to help with diarrhoea are summarised
| Participants | Octreotide Treatment | No Octreotide Treatment |
|---|---|---|
| Proportion of Subjects Reporting Stopping Completely or Missing Doses of Anti-cancer Tablets Due to Diarrhoea as Recorded in the DMD | 2 | 3 |
Collected over Up to 28 weeks post randomization (from randomization until up to and including 4 weeks after the last dose of study treatment). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Octreotide Treatment | 1/29 (3.4%) | 5/29 (17.2%) | 26/29 (89.7%) |
| No Octreotide Treatment | 0/33 (0%) | 3/33 (9.1%) | 27/33 (81.8%) |
| All Patients | 1/62 (1.6%) | 8/62 (12.9%) | 53/62 (85.5%) |
| Event | Octreotide Treatment | No Octreotide Treatment | All Patients |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 1/29 | 0/33 | 1/62 |
| Lower respiratory tract infectionInfections and infestations | 1/29 | 0/33 | 1/62 |
| VulvitisInfections and infestations | 1/29 | 0/33 | 1/62 |
| Alanine aminotransferase increasedInvestigations | 1/29 | 0/33 | 1/62 |
| ThrombosisVascular disorders | 1/29 | 0/33 | 1/62 |
| Osteonecrosis of jawMusculoskeletal and connective tissue disorders | 0/29 | 1/33 | 1/62 |
| ParaparesisNervous system disorders | 0/29 | 1/33 | 1/62 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 0/29 | 1/33 | 1/62 |
| Event | Octreotide Treatment | No Octreotide Treatment | All Patients |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 17/29 | 15/33 | 32/62 |
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 13/29 | 11/33 | 24/62 |
| AstheniaGeneral disorders | 2/29 | 7/33 | 9/62 |
| RashSkin and subcutaneous tissue disorders | 4/29 | 7/33 | 11/62 |
| AnaemiaBlood and lymphatic system disorders | 1/29 | 6/33 | 7/62 |
| Alanine aminotransferase increasedInvestigations | 4/29 | 2/33 | 6/62 |
| Aspartate aminotransferase increasedInvestigations | 4/29 | 1/33 | 5/62 |
| Blood bilirubin increasedInvestigations | 4/29 | 3/33 | 7/62 |
| NeutropeniaBlood and lymphatic system disorders | 1/29 | 4/33 | 5/62 |
| ThrombocytopeniaBlood and lymphatic system disorders | 3/29 | 3/33 | 6/62 |
| Age, Continuous(Years) | Octreotide Treatment | No Octreotide Treatment | Total |
|---|---|---|---|
| Mean | 57.4 ± 10.07 | 55.9 ± 9.08 | 56.6 ± 9.52 |
| Sex: Female, Male(Participants) | Octreotide Treatment | No Octreotide Treatment | Total |
|---|---|---|---|
| Female | 30 | 32 | 62 |
| Male | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Octreotide Treatment | No Octreotide Treatment | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 1 |
| Not Hispanic or Latino | 30 | 31 | 61 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2014 to primary completion in Oct 2017, 34 months.
Results were first posted in Jul 2019, 1 year 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Lapatinib · Capecitabine